- 现金
- 1543 元
- 精华
- 0
- 帖子
- 419
- 注册时间
- 2005-12-7
- 最后登录
- 2017-7-4
|
参考文献
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2010 version) [J]. Zhongguo Bingdubing Zazhi, 2011, 1(1):9-23. (in Chinese)
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南 (2010年版) [J]. 中国病毒病杂志, 2011, 1(1):9-23.
[2] European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection [J]. J Hepatol, 2012, 57(1):167-185.
[3] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update [J]. Hepatol Int, 2012, 6 (3):531-561.
[4] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009 [J]. Hepatology, 2009, 50(3):661-662.
[5] China Advisory Panel of Hepatitis B Virus Drug Resistance. Consensus statement on drug resistance of hepatitis B virus [J/CD]. Zhonghua Shiyan He Linchuang Ganranbing Zazhi:Electronic Edition, 2008, 2(1):90-98. (in Chinese)
乙型肝炎病毒耐药专家委员会. 乙型肝炎病毒耐药专家共识 [J/CD]. 中华实验和临床感染病杂志:电子版,2008, 2(1):90-98.
[6] China Advisory Panel of Hepatitis B Virus Drug Resistance. Consensus statement on drug resistance of hepatitis B virus:update 2009 [J/CD]. Zhonghua Shiyan He Linchuang Ganranbing Zazhi:Electronic Edition, 2009, 3(1):72-79. (in Chinese)
乙型肝炎病毒耐药专家委员会. 乙型肝炎病毒耐药专家共识: 2009年更新 [J/CD]. 中华实验和临床感染病杂志:电子版, 2009, 3(1):72-79.
[7] Yao GB, Zhu M, Cui ZY. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China [J]. J Dig Dis, 2009, 10(2):131-137.
[8] Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B [J]. Clin Infect Dis, 2003, 36(6):687-696.
[9] Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease [J]. Hepatology, 2002, 36(1):219-226.
[10] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B [J]. Gastroenterology, 2009, 136(2):486-495.
[11] Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B [J]. N Engl J Med, 2007, 357(25):2576-2588.
[12] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years [J]. Gastroenterology, 2006, 131(6):1743-1751.
[13] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [J]. Hepatology, 2008, 48(3):750-758.
[14] Zeng MD, Mao YM, Yao GB, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B [J]. Liver Int, 2012, 32(1):137-146.
[15] Yokosuka O, Takaguchi K, Fujioka S,et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection [J]. J Hepatology, 2010, 52(6):791-799.
[16] Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: viral suppression, viral resistance and clinical safety [J]. Am J Gastroenterol, 2011, 106(7):1264-1271.
[17] Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus [J]. Hepatology, 2011, 53(3):763-773.
[18] Sun MS, Wang GQ, Zhang W, et al. The current status of lamivudine-treated patients with chronic hepatitis B [J]. Zhongguo Yufang Yixue Zazhi, 2012, 13(1): 18-22. (in Chinese)
孙秘书,王贵强,张伟. 拉米夫定经治慢性乙型肝炎患者治疗现状调查分析 [J]. 中国预防医学杂志, 2012, 13(1):18-22.
[19] Suzuki F, Akuta N, Suzuki Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H [J]. J Clin Virol, 2007, 39(2):149-152.
[20] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease [J]. N Engl J Med, 2004, 351(15):1521-1531.
[21] Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma [J]. Aliment Pharmacol Ther, 2008, 28(9):1067-1077.
[22] Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine [J]. Hepatology, 2004, 40(4): 883-919.
[23] Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B [J]. Hepatology, 2000, 32(4 Pt 1):847-851.
[24] Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B [J]. J Hepatol, 2005, 42(2):173-179.
[25] Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis, 2012, 12(4):341-353
[26] Locarnini S. Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure [J]. Hepatol Int, 2008, 2(2):147-151.
[27] Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice [J]. Hepatology, 2011, 53(6):1854-1863.
[28] Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach [J]. Gastroenterology, 2008, 134(2):405-415.
[29] Liaw YF. Hepatitis flare and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy [J]. J Gastroenterol Hepatol, 2003, 18(3):246-252.
[30] Locarnini S. Molecular virology of hepatitis B virus [J]. Semin Liver Dis, 2004,24 Suppl 1:3-10.
[31] Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management [J]. Hepatology, 2007, 46(1):254-265.
[32] Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B [J]. J Hepatol, 2012, 56 Suppl 1:S112-S122.
[33] Ghany M,Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B [J]. Gastroenterology, 2007, 132(4):1574-1585.
[34] Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection [J]. Antiviral Res, 2004, 64(1):1-15.
[35] Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis [J]. J Hepatol, 2003, 39 Suppl 1:S124-S132.
[36] Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B [J]. J Hepatol, 2009, 51(1):11-20.
[37] Liu F, Chen L, Yu DM, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy [J]. Gut, 2011, 60(9):1269-1277.
[38] Chen L, Zhang Q, Yu DM, et a1. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy [J]. J Hepatol, 2009, 50(5):895-905.
[39] Xu Z, Liu Y, Xu T, et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus [J]. J Clin Virol, 2010, 48(4):270-274.
[40] Fung SK, Mazzulli T, Sherman M, et al. Pre-existing antiviral resistance mutations among treatment-naive HBV patients can be detected by a sensitive line probe assay [J]. J Hepatol, 2008, 48 Suppl 2:S256.
[41] Chotiyaputta W, Hongthanakorn C, Oberhelman K, et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs [J]. J Viral Hepat, 2012, 19(3):205-212.
[42] Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine [J]. Antimicrob Agents Chemother, 2004, 48(9):3498-3507.
[43] Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient [J]. J Hepatol, 2007, 46(3):531-538.
[44] van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues [J]. Hepatology, 2010, 51(1):73-80.
[45] Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B [J]. Gut, 2011, 60(2):247-254.
[46] Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir [J]. Antivir Ther, 2005, 10(6):727-734.
[47] Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues [J]. J Hepatol, 2010, 52(4):493-500.
[48] Locarnini S, Yuen L. Molecular genesis of drug-resistance and vaccine-escape HBV mutants [J]. Antivir Ther, 2010, 15(3Pt B):451-461.
[49] Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy [J]. Antivir Ther, 2010, 15(3 Pt B):471-475.
[50] Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy [J]. Virology, 2002, 293(2):305-313.
[51] Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model [J]. Hepatolgy, 2009, 49(5):1483-1491.
[52] Warner N,Lorcarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutanbt has a dominant negative secretion defect and alters the typical profile of viral rebound [J]. Hepatology, 2008, 48(1):88-98.
[53] Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant [J]. Antivir Ther, 2008, 13(7):875-879.
[54] Lai MW, Huang SF, Hsu CW, et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatiocellullar carcinoma developed after lamivudine therapy [J]. Antivir Ther, 2009, 14(2):249-261.
[55] Yeh CT, Chen T, Hsu CW,et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B [J]. BMC Cancer, 2011, 11:398.
[56] Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient [J]. Gastroenterology, 2006, 131(4):1253-1261.
[57] Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease [J]. Antivir Ther, 2007, 12(8):1295-1303.
[58] Liu Y, Wang C, Zhong Y, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection [J]. J Viral Hepat, 2011, 18(4):e29-e39.
[59] Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B [J]. Gastroenterology, 2003, 125(6):1714-1722.
[60] Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice [J]. Hepatology, 2011, 53(6):1854-1863.
[61] Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine [J]. J Clin Microbiol, 1999, 37(10):3338-3347.
[62] Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy [J]. Hepatology, 2006, 44(3):703-712.
[63] Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization [J]. Antivir Ther, 2005, 10(3):441-449.
[64] Stuyver L, VanGeyt C, DeGendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy [J]. J Clin Microbiol,2000, 38(2):702-707.
[65] Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay [J]. J Clin Microbiol, 2002, 40(10):3729-3734.
[66] HussainM, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir [J]. J Clin Microbiol, 2006, 44(3):1094-1097.
[67] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update [J]. Clin Gastroenterol Hepatol, 2008, 6(12):1315-1341.
[68] Hou J, Sun J, Xie Q , et al. Virological breakthrough and genotypic resistance in a randomized,
controlled study on telbivudine treatment applying roadmap concept in CHB: W76 interim analysis of effort study [J]. J Hepatol, 2012, 56 Suppl 2:S203-S204.
[69] Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response [J]. Hepatology, 2011, 54(2):443-451.
[70] Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance [J]. Aliment Pharmacol Ther, 2011, 34(4):424-431.
[71] Marcellin P, Avila C, Wursthorn K, et al. Telbivudine (LDT) plus peg-interferon(PEGIFN) in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy(PN) [J]. J Hepatol, 2010, 52 Suppl 1:S6-S7.
[72] Keeffe EB, Dieterich DT, Pawlotsky JM, et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance [J]. Clin Gastroenterol Hepatol, 2008, 6(3):268-274.
[73] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B [J]. N Engl J Med,2005,352(26): 2682-2695.
[74] Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B [J]. J Hepatol, 2008, 48(5): 728-735.
[75] Lok AS, Trihn HN, Carosi G, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide naive patients with chronic hepatitis B: the BELOW study [J]. Hepatology, 2011, 54 Suppl 1: 471A.
[76] Terraut NA. Benefits and risks of combination therapy for hepatitis B [J]. Hepatology, 2009, 49(5 Suppl):S122-S128.
[77] Dong N, He B, Zhuang H. An online questionnaire survey on awareness of antiviral treatment in patients with chronic hepatitis B [J]. Ganzang, 2009, 14(1):8-10. (in Chinese)
董南,何波,庄辉. 慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查 [J]. 肝脏, 2009, 14(1): 8-10.
[78] Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus
infection in resource-constrained settings: expert panel consensus [J]. Liver Int, 2011, 31(6):755- 761.
|
|